[{"id":"21aa57fd-3489-4d2b-b37d-e3d304aa4f47","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616209","created_at":"2021-01-19T20:33:34.222Z","updated_at":"2025-02-25T14:40:41.368Z","phase":"Phase 1/2","brief_title":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT04616209","lead_sponsor":"Precision Biotech Taiwan Corp.","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PB103"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/15/2020","start_date":" 11/15/2020","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-14"}]